| Not Yet Recruiting | Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer NCT07525349 | Assiut University | — |
| Not Yet Recruiting | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients NCT07231809 | AC.TA. S.r.l. | N/A |
| Recruiting | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract NCT07218380 | Eli Lilly and Company | Phase 3 |
| Recruiting | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Early vs Delayed Intravesical Blad-Care During BCG Therapy NCT07495072 | BLAD-HYA Group | N/A |
| Active Not Recruiting | FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer NCT06421142 | First Affiliated Hospital of Fujian Medical University | N/A |
| Not Yet Recruiting | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC NCT07189793 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Not Yet Recruiting | Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects NCT06880939 | Qilu Hospital of Shandong University | N/A |
| Recruiting | Virtual Histology of the Bladder Wall for Bladder Cancer Staging NCT04369560 | Jodi Maranchie | EARLY_Phase 1 |
| Recruiting | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bla NCT06960577 | AstraZeneca | Phase 3 |
| Recruiting | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) NCT06833073 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resectio NCT07347132 | Lahore General Hospital | N/A |
| Completed | GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile NCT06281691 | Jørgen Bjerggaard Jensen | — |
| Active Not Recruiting | Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Exa NCT06289283 | Theodor Bilharz Research Institute | — |
| Recruiting | HTL0039732 in Participants With Advanced Solid Tumours NCT05944237 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocol NCT06441110 | Fujian Medical University Union Hospital | Phase 3 |
| Completed | A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma NCT05742867 | Bristol-Myers Squibb | — |
| Terminated | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder NCT05699135 | Pfizer | — |
| Active Not Recruiting | A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer NCT05567185 | Janssen Pharmaceutical K.K. | Phase 1 |
| Unknown | Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer NCT05445648 | First Affiliated Hospital Xi'an Jiaotong University | Phase 2 |
| Completed | The Impact of Intelligent Nursing Based on Health Cloud Platform on Active Health Management of Urostomy Patie NCT07201441 | Sir Run Run Shaw Hospital | N/A |
| Recruiting | FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739 | Eli Lilly and Company | Phase 1 |
| Recruiting | Prognostic Performance of a Chemogram in Patients With Bladder Cancer. NCT06403202 | Lille Catholic University | — |
| Active Not Recruiting | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Ur NCT04919512 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanc NCT05397171 | AstraZeneca | Phase 1 / Phase 2 |
| Not Yet Recruiting | Urinary Continence of Female POPRC and OIN NCT05325216 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Recruiting | Lymphedema After Urologic Surgery NCT05264337 | Vastra Gotaland Region | — |
| Recruiting | Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Ca NCT06892860 | Queen Mary University of London | Phase 2 |
| Terminated | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer ( NCT05014139 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Unknown | Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients NCT05068180 | RenJi Hospital | Phase 4 |
| Completed | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) NCT05007106 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Effect of Pelvic Radiotherapy on the Intestinal Microbiome and Metabolome NCT04995809 | The Christie NHS Foundation Trust | — |
| Active Not Recruiting | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment NCT04706598 | Fudan University | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) NCT04922047 | RenJi Hospital | Phase 1 / Phase 2 |
| Unknown | Narrow-band Imaging Diagnostic Classification System for Bladder Tumors NCT05611762 | Qilu Hospital of Shandong University (Qingdao) | — |
| Active Not Recruiting | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non NCT04640623 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Mus NCT04658862 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer NCT04430036 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Unknown | Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC NCT04819399 | Lindis Biotech GmbH | Phase 1 |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Prospective Sample Collection for Cancer of Bladder NCT03973671 | Universitaire Ziekenhuizen KU Leuven | — |
| Active Not Recruiting | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in NCT04241185 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Ba NCT04172675 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Effect of Head Elevation on LMA Insertion NCT04229862 | Asan Medical Center | N/A |
| Withdrawn | A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) NCT04109092 | Eisai Inc. | Phase 1 |
| Terminated | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Vers NCT04149574 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer NCT07511517 | Oslo University Hospital | — |
| Completed | Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer NCT03977831 | Rigshospitalet, Denmark | N/A |
| Active Not Recruiting | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed NCT03661320 | Bristol-Myers Squibb | Phase 3 |
| Terminated | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-G NCT03519256 | Bristol-Myers Squibb | Phase 2 |
| Completed | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With NCT03258593 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer NCT03081858 | Lipac Oncology LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) NCT03459846 | AstraZeneca | Phase 2 |
| Completed | Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supre NCT03390127 | Asan Medical Center | N/A |
| Completed | A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible NCT03404791 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | TURBt With Adjuvant Cryoablation to Treat Bladder Cancer NCT02760953 | Huashan Hospital | N/A |
| Terminated | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer NCT03288545 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03219333 | Astellas Pharma Inc | Phase 2 |
| Completed | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma NCT02788201 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer NCT02612194 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer NCT02805608 | Rigshospitalet, Denmark | Phase 2 |
| Completed | The Bladder Instillation Comparison Study NCT02695771 | Corewell Health West | Phase 3 |
| Completed | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinom NCT02619253 | Nabil Adra | Phase 1 |
| Unknown | Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach NCT02696733 | Medical University of Warsaw | Phase 4 |
| Active Not Recruiting | CIK in Treating Patients With Bladder Cancer NCT02489890 | The First People's Hospital of Changzhou | Phase 2 |
| Unknown | Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surge NCT02600481 | Huadong Hospital | N/A |
| Terminated | Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer NCT02560038 | The University of Texas Health Science Center, Houston | Phase 2 |
| Unknown | Postoperative Quality of Recovery After Transurethral Resection of the Bladder NCT02534623 | General Hospital Zadar | N/A |
| Unknown | Molecular Biosensors for Detection of Bladder Cancer NCT02957370 | University of California, Irvine | — |
| Completed | Cystoscopic Imaging Collection and Enhancement pROject NCT02427321 | Biosignatures Limited | — |
| Completed | Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer NCT02381912 | Herlev Hospital | — |
| Terminated | Peri-operative Aspirin Continuation Versus Discontinuation NCT02350543 | Rabin Medical Center | Phase 4 |
| Completed | Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms NCT02430623 | Fuda Cancer Hospital, Guangzhou | N/A |
| Completed | Propofol and Sevoflurane for Catheter-Related Bladder Discomfort NCT02252445 | Seoul National University Hospital | N/A |
| Unknown | Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort NCT02228473 | Seoul National University Hospital | N/A |
| Completed | Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level NCT02778243 | Hopital Foch | N/A |
| Completed | Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort NCT02096224 | Seoul National University Hospital | N/A |
| Completed | Trimodality Treatment in Bladder Cancer NCT06395701 | Consorci Sanitari de Terrassa | — |
| Completed | Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study NCT01868087 | Jill Hamilton-Reeves, PhD RD LD | EARLY_Phase 1 |
| Completed | Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NCT02891460 | UroGen Pharma Ltd. | N/A |
| Completed | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer NCT01631552 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Cabozantinib for Advanced Urothelial Cancer NCT01688999 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radical Cystectomy, Nutrition and Convalescence NCT02238886 | Rigshospitalet, Denmark | N/A |
| Completed | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Re NCT01478685 | Celgene | Phase 1 |
| Terminated | Imaging Study for FdCyd and THU Cancer Treatment NCT01479348 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Terminated | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy NCT01435356 | European Association of Urology Research Foundation | Phase 2 |
| Terminated | Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcin NCT01342172 | Icahn School of Medicine at Mount Sinai | Phase 1 / Phase 2 |
| Terminated | Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer NCT01261299 | University of California, Davis | EARLY_Phase 1 |
| Completed | A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) NCT00978250 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer NCT00818350 | Campania Younger Oncologists Association | Phase 1 / Phase 2 |
| Completed | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Ur NCT00625664 | Sanofi | Phase 3 |
| Completed | Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment NCT00710970 | Seth Lerner | Phase 2 |
| Terminated | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for NCT00384891 | Medical Enterprises Europe B.V. | Phase 3 |
| Withdrawn | SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolut NCT02254915 | Medical Enterprises Europe B.V. | Phase 3 |